Business Wire

MA-PRECISELY

8.12.2022 15:01:43 CET | Business Wire | Press release

Share
New Research Reveals Supply Chain Resiliency and Agility are Key Drivers for Process Automation

Precisely, the global leader in data integrity, in collaboration with SAPinsider, today announced the results of new global research that highlights the importance of process automation in building robust supply chains. Findings from the new benchmark report, Process Automation in Supply Chain, show that 51% of respondents cite resiliency as the top supply chain concern driving the need for process automation, with agility close behind at 46%. A backdrop of disruptive world events means businesses are increasingly battling against global supply chain disruption, as well as mounting pressures to keep pace with changing consumer preferences for digital, local, and sustainable goods – resulting in an urgent need for supply chain transformation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221208005434/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

51% of business leaders cite resiliency as top supply chain concern driving need for process automation (Graphic: Business Wire)

The research found that 89% of respondents believe process automation in the supply chain is either “important” or “very important” to attain digital transformation objectives. However, a major gap remains between where the industry needs to be and where it currently stands: Nearly three-fourths (72%) indicated that less than 50% of their supply chain processes are currently automated, with this dropping to just 25% for a further one-third of the respondents.

“With recent world events including the COVID-19 pandemic, the war in Ukraine, and impacts from climate change, it’s no surprise that supply chain resiliency is top of mind for businesses worldwide,” said Mark Vigoroso, Chief Content Officer at SAPinsider. “While adoption of technologies has been slow to-date, the need to create a resilient supply chain ecosystem has never been more apparent, and we’re seeing organizations increasingly turn to process automation as a way to build robust supply chain capabilities and help navigate the uncertainty in the market.”

“These new findings from SAPinsider highlight the importance of automation when it comes to complex, data intensive, SAP processes, such as for supply chain,” said John Reda, SVP – Product Management for Data Integration at Precisely. “The Precisely Automate Evolve platform, formerly Winshuttle Evolve, helps customers to gain agility and speed by simplifying and streamlining processes. The flexible, scalable nature of the platform helps create and maintain resilient supply chains - delivering increased efficiency, visibility and governance that improve results and reduce the risks inherent in today’s unpredictable business environment.”

The research additionally shows that the key objectives for deploying process automation have become more strategic over time, and include the realization of benefits such as:

  • End-to-end process visibility (82%)
  • Increased process efficiency (79%)
  • Defining and documenting standardization (77%)
  • Integrated processes across end-to-end supply chain (75%)
  • Building internal skillset (72%)

It also uncovers an increased appetite to explore more advanced automation technologies as businesses plan for 2023 and beyond -- with nearly half of all respondents (47%) stating intelligent automation, such as AI and machine learning, is a key capability they are considering implementing over the next 24 months.

“Ultimately, supply chain resilience relies upon a programmatic approach for improving end-to-end process visibility and risk monitoring. To be successful, supply chains must become both digital and autonomous to keep pace with disruptive global events and changing consumer expectations,” continued Reda. “It’s clear that process automation is critical, but the success of digitized processes and workflows will also rely upon the accuracy, consistency and context of the data feeding them. Supply chain transformation, fueled by data integrity, will be the key to confident decision-making during the uncertain times ahead.”

Read the full SAPinsider Benchmark Report Process Automation in Supply Chain here or for further insights on the role of process automation in building robust supply chains, view our on-demand webinar “Process Automation Trends in SAP Supply Chain for 2023” here.

About SAPinsider and Survey Methodology
SAPinsider comprises the largest and fastest growing SAP membership group worldwide, with more than 500,000 members across 205 countries. The Supply Chain Research Report, conducted in partnership with Precisely, surveyed SAP Insider members between July and September 2022 to gauge the use and future investment of process automation in supply chain. The survey was administered to 105 members of the SAPinsider Community and generated responses from across a wide range of geographies, industries, and company sizes.

About Precisely
Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005434/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye